Peer-reviewed veterinary case report
How chemotherapy affects blood clotting in dogs with lymphoma
By Eberle, N & Mischke, R·Published in Veterinary journal (London, England : 1997)·2010·Small Animal Clinic, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Influence of a cyclic combination chemotherapeutic protocol on primary haemostasis in dogs suffering from malignant lymphoma.
- Species:
- dog
Plain-English summary
A group of 17 dogs with malignant lymphoma (a type of cancer) received a combination of chemotherapy drugs, including asparaginase, vincristine, doxorubicin, and prednisolone, to treat their condition. During the first four weeks of treatment, their platelet counts were monitored, showing an increase in the second week before decreasing again by the fourth week. Importantly, the study found that the chemotherapy did not significantly affect the dogs' platelet function, meaning their blood clotting ability remained stable throughout the treatment. This suggests that the chemotherapy protocol used is safe in terms of maintaining normal blood function.
People also search for: dog lymphoma treatment · chemotherapy side effects in dogs · dog platelet count increase
Abstract
The purpose of this study was to examine the influence of cyclic combination chemotherapy on primary haemostasis in dogs with malignant lymphoma. Seventeen dogs receiving cytostatic treatment for high-grade lymphoma were included in the study. The dogs were treated with a Madison-Wisconsin derived protocol, which included asparaginase, vincristine, doxorubicin and prednisolone. At different time points during the first 4 weeks of induction, platelet count, capillary bleeding time, analysis of the platelet function using the platelet function analyser PFA-100, and platelet aggregation by the Born-method were measured. The most obvious changes were found for median values of the platelet count, which increased significantly from 210,000/microL before induction to 349,000/microL during the second week of induction (P=0.0010). Median platelet count subsequently decreased by the fourth week of treatment (Friedman-test: P<0.0001). None of the parameters of platelet function (capillary bleeding time, automatic platelet function analysis, aggregation maximum) showed significant changes with time (P>0.05, Friedman-test). The results did not suggest that significant platelet dysfunction was induced by the chemotherapeutic protocol used in the study.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19185520/